Free Trial
NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

$19.96
-0.04 (-0.20%)
(As of 09/20/2024 ET)

About Bausch + Lomb Stock (NYSE:BLCO)

Key Stats

Today's Range
$19.67
$20.10
50-Day Range
$15.30
$20.00
52-Week Range
$13.16
$21.00
Volume
616,222 shs
Average Volume
560,222 shs
Market Capitalization
$7.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.59
Consensus Rating
Moderate Buy

Company Overview

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 49th Percentile

Bausch + Lomb scored higher than 49% of companies evaluated by MarketBeat, and ranked 597th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bausch + Lomb has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bausch + Lomb has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bausch + Lomb's stock forecast and price target.
  • Earnings Growth

    Earnings for Bausch + Lomb are expected to grow by 43.33% in the coming year, from $0.60 to $0.86 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bausch + Lomb is -20.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bausch + Lomb is -20.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Bausch + Lomb has a PEG Ratio of 1.47. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bausch + Lomb has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bausch + Lomb's valuation and earnings.
  • Percentage of Shares Shorted

    5.82% of the float of Bausch + Lomb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch + Lomb has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch + Lomb has recently increased by 15.71%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bausch + Lomb does not currently pay a dividend.

  • Dividend Growth

    Bausch + Lomb does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.82% of the float of Bausch + Lomb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch + Lomb has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch + Lomb has recently increased by 15.71%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Bausch + Lomb has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Bausch + Lomb this week, compared to 3 articles on an average week.
  • Search Interest

    Only 8 people have searched for BLCO on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Bausch + Lomb to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bausch + Lomb insiders have bought more of their company's stock than they have sold. Specifically, they have bought $505,035.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Institutions

    Only 11.07% of the stock of Bausch + Lomb is held by institutions.

  • Read more about Bausch + Lomb's insider trading history.
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

BLCO Stock News Headlines

Private Equity Interest Signals Upside for Bausch + Lomb: A Buy Rating Justified
We recommended Nvidia in 2016, now we’re recommending this…
The AI boom is just getting started. And the real wealth has still to be made…
Bausch + Lomb (NYSE:BLCO) Sees Large Volume Increase
Bausch + Lomb's (BLCO) Hold Rating Reiterated at Needham & Company LLC
See More Headlines

BLCO Stock Analysis - Frequently Asked Questions

Bausch + Lomb's stock was trading at $17.06 at the start of the year. Since then, BLCO stock has increased by 17.0% and is now trading at $19.96.
View the best growth stocks for 2024 here
.

Bausch + Lomb Co. (NYSE:BLCO) announced its earnings results on Wednesday, July, 31st. The company reported $0.13 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.13. The company's revenue for the quarter was up 17.5% compared to the same quarter last year.

Bausch + Lomb (BLCO) raised $788 million in an initial public offering (IPO) on Friday, May 6th 2022. The company issued 35,000,000 shares at a price of $21.00-$24.00 per share.

Bausch + Lomb's top institutional shareholders include Whitebox Advisors LLC (0.44%), Clearline Capital LP (0.20%), Point72 Europe London LLP (0.19%) and Point72 Asset Management L.P. (0.18%).
View institutional ownership trends
.

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
7/31/2024
Today
9/20/2024
Next Earnings (Estimated)
11/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Medical Equipment
Fax
N/A
Employees
13,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.59
High Stock Price Target
$23.00
Low Stock Price Target
$15.50
Potential Upside/Downside
-6.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$-260,000,000.00
Pretax Margin
-5.74%

Debt

Sales & Book Value

Annual Sales
$4.50 billion
Cash Flow
$2.41 per share
Book Value
$19.72 per share

Miscellaneous

Free Float
N/A
Market Cap
$7.02 billion
Optionable
Optionable
Beta
0.46
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NYSE:BLCO) was last updated on 9/20/2024 by MarketBeat.com Staff
From Our Partners